Zhejiang Hisun Pharmaceutical Co., Ltd.

XSSC:600267 Stock Report

Market Cap: CN¥10.0b

Zhejiang Hisun Pharmaceutical Balance Sheet Health

Financial Health criteria checks 5/6

Zhejiang Hisun Pharmaceutical has a total shareholder equity of CN¥8.5B and total debt of CN¥4.6B, which brings its debt-to-equity ratio to 54.5%. Its total assets and total liabilities are CN¥16.3B and CN¥7.8B respectively. Zhejiang Hisun Pharmaceutical's EBIT is CN¥236.5M making its interest coverage ratio -1.8. It has cash and short-term investments of CN¥1.5B.

Key information

54.5%

Debt to equity ratio

CN¥4.63b

Debt

Interest coverage ratio-1.8x
CashCN¥1.48b
EquityCN¥8.50b
Total liabilitiesCN¥7.76b
Total assetsCN¥16.26b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 600267's short term assets (CN¥5.8B) do not cover its short term liabilities (CN¥6.2B).

Long Term Liabilities: 600267's short term assets (CN¥5.8B) exceed its long term liabilities (CN¥1.5B).


Debt to Equity History and Analysis

Debt Level: 600267's net debt to equity ratio (37%) is considered satisfactory.

Reducing Debt: 600267's debt to equity ratio has reduced from 121.4% to 54.5% over the past 5 years.

Debt Coverage: 600267's debt is well covered by operating cash flow (35.4%).

Interest Coverage: 600267 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies